Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a Phase 2a multicenter, randomized study titled ‘A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn’s Disease.’ The study aims to evaluate the effectiveness and safety of targeted therapies for adults suffering from moderate to severe Crohn’s Disease, a chronic inflammatory condition of the digestive tract. This research is significant as current treatments may not be effective for all patients or may lose efficacy over time.
The study tests three drugs: Risankizumab, ABBV-382, and Lutikizumab. These are administered either as monotherapies or in combination, through subcutaneous injections or intravenous infusions, to assess their impact on Crohn’s Disease symptoms.
The study employs a randomized, sequential intervention model without masking, focusing on treatment as its primary purpose. Participants are randomly assigned to different treatment groups, and the study includes a 12-week induction period, a 12-week maintenance period, and an optional long-term extension.
The study began on August 8, 2024, with a primary completion date yet to be announced. The latest update was submitted on August 18, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This study update could influence AbbVie’s stock performance and investor sentiment, given the potential for new effective treatments in the competitive Crohn’s Disease market. Success in this study could position AbbVie favorably against competitors.
The study is ongoing, and further details are available on the ClinicalTrials portal.